- Home
- PALI vs EDIT Comparison
PALI vs EDIT Comparison
Compare PALI & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PALI | EDIT |
|---|---|---|
| Founded | 1996 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 240.2M | 206.0M |
| IPO Year | 2019 | 2016 |
Fundamental Metrics
Financial Performance| Metric | PALI | EDIT |
|---|---|---|
| Price | $1.63 | $1.94 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $13.00 | $4.50 |
| AVG Volume (30 Days) | ★ 3.0M | 1.4M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | $260,000.00 | ★ $31,937,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1500.39 | 132.64 |
| 52 Week Low | $0.55 | $0.91 |
| 52 Week High | $2.64 | $4.54 |
Technical Indicators
Market Signals| Indicator | PALI | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 43.63 | 46.89 |
| Support Level | $1.57 | $1.66 |
| Resistance Level | $1.93 | $2.36 |
| Average True Range (ATR) | 0.11 | 0.16 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 16.22 | 41.13 |
Price Performance
Historical ComparisonAbout PALI Palisade Bio Inc.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.